Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30005190 | 1.00 | CYP3A4 (0.50) | CYP3A4ALDH1A1THRBTSHRTP53 | |
| Hydrochloric Acid SCHEMBL15573674 | 0.97 | CYP3A4 (0.48) | CYP3A4ALDH1A1THRBTSHRTP53 | |
| SCHEMBL1029756 | 0.86 | CYP3A4 (0.58) | CYP3A4ALDH1A1THRBTSHRTP53 | |
| SCHEMBL15575090 | 0.81 | TTR (0.46) | ALDH1A1THRBTSHRTP53CA1 | |
| SCHEMBL111459 | 0.80 | CES2 (0.41) | CYP3A4ALDH1A1THRBTSHRTP53 | |
| SCHEMBL31246242 | 0.79 | CYP3A4 (0.50) | CYP3A4ALDH1A1THRBTSHRTP53 | |
| SCHEMBL17964095 | 0.79 | CYP3A4 (0.50) | CYP3A4ALDH1A1THRBTSHRTP53 | |
| Bromide SCHEMBL31241400 | 0.77 | CES2 (0.39) | CYP3A4ALDH1A1TSHRTP53CA1 | |
| Iodide SCHEMBL30689240 | 0.77 | CES2 (0.39) | CYP3A4ALDH1A1TSHRTP53CA1 | |
| SCHEMBL1806961 | 0.75 | CYP3A4 (0.46) | CYP3A4ALDH1A1THRBTSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235686-A1 | FLUOROCAMPTOTHECIN COMPOUNDS, CONJUGATES, AND METHODS THEREOF | Aarvik Therapeutics, Inc. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-12161625-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4323350-A1 | ISOINDOLINONE COMPOUNDS | Monte Rosa Therapeutics AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| US-20240051936-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-02-15 | — | — | US | disclosed |
| CN-117242060-A | Isoindolinone compounds | 蒙特罗萨医疗公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20230391752-A1 | PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES | CHULALONGKORN UNIVERSITY (TH) | 2023-12-07 | — | — | US | disclosed |
| EP-1470121-B1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| EP-1515965-B1 | PHENYLAMINOPYRIMIDINES AND THEIR USE AS RHO-KINASE INHIBITORS | BAYER SCHERING PHARMA AG (DE) | 2010-10-06 | — | — | EP | disclosed |
| US-20050192304-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2005-09-01 | — | — | US | disclosed |
| US-6924290-B2 | Rho-kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| EP-1515965-A1 | PHENYLAMINOPYRIMIDINES AND THEIR USE AS RHO-KINASE INHIBITORS | Bayer Aktiengesellschaft (DE) | 2005-03-23 | — | — | EP | disclosed |
| EP-1470121-A1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040002508-A1 | Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders | BAYER CORPORATION | 2004-01-01 | — | — | US | disclosed |
| WO-2003106450-A1 | PHENYLAMINOPYRIMIDINES AND THEIR USE AS RHO-KINASE INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003062225-A1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053179-A1 | Rho-Kinase Inhibitors | CIT, ROCK1, ROCK2 | CYP3A4 2878/4885ALDH1A1 3690/4885THRB 1531/4885 |
| US-20230391752-A1 | PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES | GLS2, PYGL, CPS1 | CYP3A4 34/4885ALDH1A1 433/4885THRB 2570/4885 |
| US-12161625-B2 | Substituted pyrrolizine compounds and uses thereof | HMBS, DHFR, HCCS | CYP3A4 218/4885ALDH1A1 4332/4885THRB 4054/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | CYP3A4 684/4885ALDH1A1 1142/4885THRB 1643/4885 |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | CYP3A4 684/4885ALDH1A1 1142/4885THRB 1643/4885 |
| US-20240051936-A1 | ISOINDOLINONE COMPOUNDS | CRBN, CDR2, POU2F2 | CYP3A4 1729/4885ALDH1A1 1907/4885THRB 2172/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | CYP3A4 684/4885ALDH1A1 1142/4885THRB 1643/4885 |
| US-20040002508-A1 | Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders | CIT, ROCK1, RHOT2 | CYP3A4 2456/4885ALDH1A1 2590/4885THRB 2947/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | CYP3A4 4304/4885ALDH1A1 4276/4885THRB 2089/4885 |
| US-20050192304-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | CYP3A4 2878/4885ALDH1A1 3690/4885THRB 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.